Pages that link to "Item:Q70258"
From MaRDI portal
The following pages link to Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer (Q70258):
Displaying 50 items.
- Continual Reassessment Method for Partial Ordering (Q2893418) (← links)
- Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial (Q2931051) (← links)
- A Bayesian adaptive dose-finding algorithm for balancing individual- and population-level ethics in Phase I clinical trials (Q2958397) (← links)
- Incorporating Individual and Collective Ethics into Phase I Cancer Trial Designs (Q3013989) (← links)
- A class of designs for Phase I cancer clinical trials combining Bayesian and likelihood approaches (Q3019496) (← links)
- A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents (Q3064270) (← links)
- Sequential Methods in Multi-Arm Clinical Trials (Q3068083) (← links)
- Dose-Finding Based on Feasibility and Toxicity in T-cell Infusion Trials (Q3078842) (← links)
- Dose-Finding Designs for HIV Studies (Q3078854) (← links)
- Monitoring the Rates of Composite Events with Censored Data in Phase II Clinical Trials (Q3078908) (← links)
- On the Use of Nonparametric Curves in Phase I Trials with Low Toxicity Tolerance (Q3078934) (← links)
- Curve-Free and Model-Based Continual Reassessment Method Designs (Q3078936) (← links)
- A Simple Technique to Evaluate Model Sensitivity in the Continual Reassessment Method (Q3079010) (← links)
- Directed Walk Designs for Dose-Response Problems with Competing Failure Modes (Q3079102) (← links)
- A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents (Q3183236) (← links)
- Dynamic calibration of pharmacokinetic parameters in dose-finding studies (Q3303574) (← links)
- Continual reassessment method with multiple toxicity constraints (Q3303685) (← links)
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios (Q3436524) (← links)
- Designs for Single- or Multiple-Agent Phase I Trials (Q3445286) (← links)
- A Statistical Framework for Quantile Equivalence Clinical Trials with Application to Pharmacokinetic Studies that Bridge from HIV‐Infected Adults to Children (Q3549403) (← links)
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials (Q3576931) (← links)
- A bayesian predictive approach to sequential search for an optimal dose: Parametric and nonparametric models (Q3598291) (← links)
- Sequential method of estimating the LD<sub>50</sub> using a modified up-and-down rule (Q4298667) (← links)
- Designs foe phase i cancer clinical trials with differentiation of graded toxicity (Q4548226) (← links)
- The role of minimal sets in dose finding studies (Q4559466) (← links)
- A Curve‐Free Method for Phase I Clinical Trials (Q4667490) (← links)
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities (Q4670477) (← links)
- Phase I (or Phase II) Dose-Ranging Clinical Trials: Proposal of a Two-Stage Bayesian Design (Q4796210) (← links)
- SEQUENTIAL METHODS IN CLINICAL TRIALS* (Q4804482) (← links)
- A Semiparametric Sequential Algorithm for Estimation of Dose–Response Curve (Q4924128) (← links)
- Book Reviews (Q4962458) (← links)
- (Q4998881) (← links)
- Patient-specific dose finding in phase I clinical trials (Q5036370) (← links)
- Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials (Q5050425) (← links)
- Review of Statistical Treatment for Oncology Dose-Escalation Trial with Prolonged Evaluation Window or Fast Enrollment (Q5051094) (← links)
- (Q5072154) (← links)
- A new design of the continual reassessment method (Q5082671) (← links)
- Impact of different model structure and prior distribution in continual reassessment method (Q5087922) (← links)
- The adaptive accelerated biased coin design for phase I clinical trials (Q5124969) (← links)
- Simple benchmark for complex dose finding studies (Q5170208) (← links)
- A study of the probit model with latent variables in Phase I clinical trials (Q5220814) (← links)
- Dose‐finding methods for Phase I clinical trials using pharmacokinetics in small populations (Q5280197) (← links)
- Adaptive designs for binary treatment responses in phase III clinical trials: controversies and progress (Q5424121) (← links)
- Ethical considerations concerning treatment allocation in drug development trials (Q5424156) (← links)
- The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach (Q5427414) (← links)
- Designs for Phase I Clinical Trials with Multiple Courses of Subjects at Different Doses (Q5434918) (← links)
- Statistical Properties of a Modified Accelerated Design for Phase I Cancer Clinical Trials (Q5438331) (← links)
- The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach (Q5449918) (← links)
- Implementation of a Bayesian Design in a Dose‐Escalation Study of an Experimental Agent in Healthy Volunteers (Q5450494) (← links)
- Retrospective Analysis of Sequential Dose‐Finding Designs (Q5717156) (← links)
